Given that fosfomycin and linezolid are the last-resort antibiotics for treating infections caused by VRE, the co-occurrence of fosB and optrA in clinical strains may seriously compromise the effectiveness of clinical therapy and is another potential threat to public health. Here, FOSB is linked to infection.